Sameer Vinod Shah, Chairman and Managing Director of Chembond Material Technologies Limited, has acquired 33,425 equity shares of the company through open market transactions, as disclosed under SEBI's Substantial Acquisition of Shares and Takeovers (SAST) Regulations.

Share Acquisition Details

The acquisition was completed across two trading sessions in January 2026, with specific transaction details as follows:

Shareholding Pattern Changes

The acquisition has resulted in a marginal increase in Shah's shareholding in the company:

Company Capital Structure

Chembond Material Technologies Limited maintains a stable equity capital structure with no changes following this transaction:

• Total Equity Capital: Rs. 6,72,41,440
• Number of Shares: 1,34,48,288 shares of Rs. 5 each
• Listing: BSE Limited (Scrip Code: 530871) and National Stock Exchange of India Limited (Scrip Code: CHEMBOND)

Regulatory Compliance

The disclosure was made in accordance with Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Shah, being a promoter and the Chairman & Managing Director, is required to disclose such acquisitions to maintain transparency in shareholding patterns.

The acquisition represents a routine open market purchase by the promoter, with no encumbrances, voting rights other than shares, or convertible securities involved in the transaction. The company's total diluted share capital remains unchanged at Rs. 6,72,41,440.

Chembond Material Technologies Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025, showing mixed performance with revenue growth offset by declining profitability due to exceptional charges.

Financial Performance Overview

The company's consolidated results revealed contrasting trends in revenue and profitability metrics. While the top line demonstrated robust growth, bottom line performance was significantly impacted by one-time charges related to regulatory changes.

Exceptional Items Impact

The quarter's profitability was significantly affected by exceptional charges totaling ₹179.61 crores. This substantial impact stemmed from incremental gratuity expenses following the notification of new Labour Codes effective from November 21, 2025. The company assessed and accounted for this regulatory change as an exceptional item, which substantially reduced the quarter's net profit.

Without these exceptional charges, the company's profit before exceptional items and tax stood at ₹476.09 crores, representing a 53.4% increase from ₹310.33 crores in the corresponding quarter of the previous year.

Nine-Month Performance

The nine-month period ending December 31, 2025, showed similar trends with revenue growth accompanied by profit decline due to exceptional items.

Segment-wise Performance

The company operates through two primary business segments, both contributing to the overall revenue growth during the quarter.

The Animal Health segment showed particularly strong performance with significantly improved profitability compared to the previous year, while the Specialty Chemicals segment maintained steady performance levels.

Board Meeting and Regulatory Compliance

The results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on January 16, 2026. The Board meeting commenced at 11:00 a.m. and concluded at 17:15 p.m. The company also noted the grant of Stock Options by the Nomination & Remuneration Committee.

In compliance with insider trading regulations, the trading window for Directors, Officers, Designated persons and their immediate relatives will remain closed till 48 hours post the outcome of Board meeting, i.e., till Sunday, January 18, 2026.

Operational Metrics

The company's operational efficiency remained robust despite the challenging quarter. Total expenses increased to ₹5,968.96 crores from ₹5,013.70 crores in Q3FY25, primarily driven by higher material costs of ₹3,738.10 crores and increased employee benefit expenses of ₹982.54 crores. Other income surged to ₹155.54 crores from ₹19.41 crores in the corresponding quarter last year.

The company maintained its paid-up equity share capital at ₹672.41 crores with a face value of ₹5 per share. The financial results have been subjected to limited review by statutory auditors M/s. Kastury & Talati, Chartered Accountants.